Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives

por Narayan, Vivek, Haas, Naomi Balzer
Publicado 2016

When Clot Is Tumor: A Roadmap to Anticoagulation in Renal Cell Carcinoma With Tumor Thrombus

por Hsu, Miles, Balzer-Haas, Naomi
Publicado 2022

Use of Bone Resorption Inhibitors in Metastatic Castration-Resistant Prostate Cancer—20 Years Later, and the Answer Is Still Yes

por Takvorian, Samuel U., Haas, Naomi B.
Publicado 2021

Phase 1b/2 trial of Ipilimumab, Nivolumab, and Ciforadenant (INC) (adenosine A2a receptor antagonist) in first-line advanced renal cell carcinoma

por Beckermann, Kathryn, Rini, Brian, Haas, Naomi, George, Daniel, Jonasch, Eric
Publicado 2023

Phase I-II study of ADXS31-142 alone and in combination with pembrolizumab in patients with previously treated metastatic castration-resistant prostate cancer (mCRPC): the KEYNOTE-...

por Haas, Naomi B, Stein, Mark N, Tutrone, Ronald, Perini, Rodolfo, Denker, Andrew, Mauro, David, Fong, Lawrence
Publicado 2015

Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras

por Li, Pengxiang, Wong, Yu‐Ning, Armstrong, Katrina, Haas, Naomi, Subedi, Prasun, Davis‐Cerone, Margaret, Doshi, Jalpa A.
Publicado 2015

ADXS31142 Immunotherapy ± Pembrolizumab Treatment for Metastatic Castration-Resistant Prostate Cancer: Open-Label Phase I/II KEYNOTE-046 Study

por Stein, Mark N, Fong, Lawrence, Tutrone, Ronald, Mega, Anthony, Lam, Elaine T, Parsi, Megan, Vangala, Surya, Gutierrez, Andres A, Haas, Naomi B
Publicado 2022

Incidence of Bladder Cancer in Patients With Type 2 Diabetes Treated With Metformin or Sulfonylureas

por Mamtani, Ronac, Pfanzelter, Nick, Haynes, Kevin, Finkelman, Brian S., Wang, Xingmei, Keefe, Stephen M., Haas, Naomi B., Vaughn, David J., Lewis, James D.
Publicado 2014

Adherence to oral therapies among patients with renal cell carcinoma: Post hoc analysis of the ECOG‐ACRIN E2805 trial

por Murphy, Caitlin C., Fullington, Hannah M., Gerber, David E., Bowman, Isaac Alex, Puligandla, Maneka, Dutcher, Janice P., DiPaola, Robert S., Haas, Naomi B.
Publicado 2021

Novel Redirected T–Cell Immunotherapies for Advanced Prostate Cancer

por Dorff, Tanya B., Narayan, Vivek, Forman, Stephen J., Zang, Peter D., Fraietta, Joseph A., June, Carl H., Haas, Naomi B., Priceman, Saul J.
Publicado 2022

A Phase II Trial of the Epothilone B Analog Ixabepilone (BMS-247550) in Patients with Metastatic Melanoma

por Ott, Patrick A., Hamilton, Anne, Jones, Amanda, Haas, Naomi, Shore, Tsiporah, Liddell, Sandra, Christos, Paul J., Doyle, L. Austin, Millward, Michael, Muggia, Franco M., Pavlick, Anna C.
Publicado 2010

Safety of enzalutamide in patients with metastatic castration‐resistant prostate cancer previously treated with docetaxel: Expanded access in North America

por Joshua, Anthony M., Shore, Neal D., Saad, Fred, Chi, Kim N., Olsson, Carl A., Emmenegger, Urban, Scholz, Mark, Berry, William, Mukherjee, Som D., Winquist, Eric, Haas, Naomi B., Foley, Margaret A., Dmuchowski, Carl, Perabo, Frank, Hirmand, Mohammad, Hasabou, Nahla, Rathkopf, Dana
Publicado 2015

Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A)

por Atkins, Michael B., Jegede, Opeyemi A., Haas, Naomi B., McDermott, David F., Bilen, Mehmet A., Stein, Mark, Sosman, Jeffrey A., Alter, Robert, Plimack, Elizabeth R., Ornstein, Moshe, Hurwitz, Michael, Peace, David J., Signoretti, Sabina, Denize, Thomas, Cimadamore, Alessia, Wu, Catherine J., Braun, David, Einstein, David, Catalano, Paul J., Hammers, Hans
Publicado 2022

Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)

por Atkins, Michael B, Jegede, Opeyemi A, Haas, Naomi B, McDermott, David F, Bilen, Mehmet A, Stein, Mark, Sosman, Jeffrey A, Alter, Robert, Plimack, Elizabeth R, Ornstein, Moshe C, Hurwitz, Michael, Peace, David J, Signoretti, Sabina, Denize, Thomas, Cimadamore, Alessia, Wu, Catherine J, Braun, David, Einstein, David, Catalano, Paul J, Hammers, Hans
Publicado 2023

BLIMP1 and NR4A3 Transcription Factors Reciprocally Regulate Antitumor CAR T-cell Stemness and Exhaustion

por Jung, In-Young, Narayan, Vivek, McDonald, Sierra, Rech, Andrew J., Bartoszek, Robert, Hong, Gwanui, Davis, Megan M., Xu, Jun, Boesteanu, Alina C., Barber-Rotenberg, Julie S., Plesa, Gabriela, Lacey, Simon F., Jadlowsky, Julie K., Siegel, Donald L., Hammill, Dana M., Cho-Park, Park F., Berger, Shelley L., Haas, Naomi B., Fraietta, Joseph A.
Publicado 2022

A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours

por Maity, Amit, Mick, Rosemarie, Huang, Alexander C., George, Sangeeth M., Farwell, Michael D., Lukens, John N., Berman, Abigail T., Mitchell, Tara C., Bauml, Josh, Schuchter, Lynn M., O’Hara, Mark, Lin, Lilie L., Demichele, Angela, Christodouleas, John P., Haas, Naomi B., Patsch, Dana M., Hahn, Stephen M., Minn, Andy J., Wherry, E. John, Vonderheide, Robert H.
Publicado 2018

Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors

por Piha-Paul, Sarina A, Hann, Christine L, French, Christopher A, Cousin, Sophie, Braña, Irene, Cassier, Phillippe A, Moreno, Victor, de Bono, Johann S, Harward, Sara Duckworth, Ferron-Brady, Geraldine, Barbash, Olena, Wyce, Anastasia, Wu, Yuehui, Horner, Thierry, Annan, Meg, Parr, Nigel J, Prinjha, Rabinder K, Carpenter, Christopher L, Hilton, John, Hong, David S, Haas, Naomi B, Markowski, Mark C, Dhar, Arindam, O’Dwyer, Peter J, Shapiro, Geoffrey I
Publicado 2019